A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease Post author: Post published:May 6, 2026 Post category: Continue ReadingA Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
Safety, Tolerability, PK, and PD Study of PGN-EDODM1 in Participants With Myotonic Dystrophy Type 1 Post author: Post published:May 6, 2026 Post category: Continue ReadingSafety, Tolerability, PK, and PD Study of PGN-EDODM1 in Participants With Myotonic Dystrophy Type 1
A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases Post author: Post published:May 6, 2026 Post category: Continue ReadingA Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases
GCC19CART for Patients With Metastatic Colorectal Cancer Post author: Post published:May 6, 2026 Post category: Continue ReadingGCC19CART for Patients With Metastatic Colorectal Cancer
Trial to Evaluate Safety and Efficacy of KPI-012 Ophthalmic Solution in Participants With PCED Post author: Post published:May 6, 2026 Post category: Continue ReadingTrial to Evaluate Safety and Efficacy of KPI-012 Ophthalmic Solution in Participants With PCED
RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis Post author: Post published:May 6, 2026 Post category: Continue ReadingRESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis
Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy)) Post author: Post published:May 6, 2026 Post category: Continue ReadingStudy of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy))
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing Post author: Post published:May 6, 2026 Post category: Continue ReadingSolid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
CMV-specific HIV-CAR T Cells as Immunotherapy for HIV/AIDS Post author: Post published:May 6, 2026 Post category: Continue ReadingCMV-specific HIV-CAR T Cells as Immunotherapy for HIV/AIDS
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression Post author: Post published:May 6, 2026 Post category: Continue ReadingA Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
